ABL acquires Fedialis Medica

ABL continues developing its technology offer with Nadis(r) technology as a specialized patient management system. Nadis is widely used in France, this completes the offer for the French market in plus of microbiology reagents and software. Please see more details in the full press release.

New Diagnostics Test and Technology for Hepatitis C

ABL inked an agreement with Inserm on a test and related IP and know-how intended for viral hepatitis C. Please see more details in the full press release.

Combining Ion Torrent sequencing systems and the DeepChek Suite Software

ABL is pleased to invite you to attend the viral typing webinar held with Thermo Fisher Scientific about the combination of their next generation sequencing systems and the ABL DeepChek downstream analysis software, for HIV, HBV and HCV. Tuesday, 10th May 2016 -- 5 pm CET / 4 pm GMT / 11 am EST Register now for this free viral typing webinar.

New commercial agreement for ViroScore® and DeepChek®

ABL inked a distribution agreement with Thermo Fisher Scientific for ViroScore and DeepChek, downstream analysis softwares for Sanger and Next Generation Sequencing respectively. These are also available on Thermo Fisher Cloud. See the press release.

ABL Group launches early access program

ABL group is pleased to announce the launch of an early access program (EAP) of its first genotyping DeepChek® assay for HCV NS5B. Further reagents will come soon to complete ABL Group's offer for Sanger and Next Generation Sequencing. These reagents will be completed with data analysis software, ViroScore® and DeepChek®. To know more, please click here.

A methodology to help doctors choosing the most efficient treatment for hepatitis C

Barcelona, 16th February 2015. Researchers from Vall d’Hebron Research Institute (VHIR) have developed a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations. The study, published in the Journal of Clinical Microbiology, is a collaboration between all the members of the Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Roche and ABL. It is funded with the CDTI MINECO IDI 20110115. View more (EN)
View more (ES)

Extension of DeepChek®-HIV portfolio with the use of PyroVir software

Advanced Biological Laboratories (ABL) S.A., today announced the signing of an exclusive worldwide license for commercial use of the PyroVir software and related knowledge database and know-how with the French National Institute of Health and Medical Research (Inserm) subsidiary, Inserm Transfert SA, and the Centre Hospitalier Universitaire de Toulouse.
View more

HepatiC® trademark registration

ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252. The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antiviral Agents which has been developed together with the Spanish Association for Liver Diseases.

ABL signs agreement with UH Case Medical Center to offer HIV drug resistance tests

University Hospitals (UH) Case Medical Center has signed an agreement with Advanced Biological Laboratories (ABL), to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS).
See the press release.

See the press release.

https://sg.finance.yahoo.com/news/advanced-biological-laboratories-signs-agreement-130000299.html

http://www.eurekalert.org/pub_releases/2015-01/uhcm-abl011315.php

https://www.genomeweb.com/business-news/abl-university-hospitals-collaborate-ngs-hiv-drug-resistance-assay

University Hospitals signs agreement with Luxembourg company to offer new HIV drug resistance test.